Evidence map›Paper›PMID 33608748›Full record

ArticleClinical oral investigations2021

Demineralization prevention with a new antibacterial restorative composite containing QASi nanoparticles: an in situ study.

Peter Rechmann, Charles Q Le, Benjamin W Chaffee, Beate M T Rechmann

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical oral investigations, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04059250 (Nobio In Situ Clinical Study - Pilot Study), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04059250 nacompletednot on this map

Nobio In Situ Clinical Study - Pilot Study

TypeinterventionalSponsorUniversity of California, San FranciscoRan2019 to 2020Enrolled25ConditionsDental Caries, Denture, Partial, RemovableArmsNobio composite, traditional composite
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Peter RechmannDepartment of Preventive and Restorative Dental Sciences, School of Dentistry, University of California, San Francisco, 707 Parnassus Avenue, San Francisco, CA, 94143, USA. Peter.Rechmann@ucsf.edu.ORCID http://orcid.org/0000-0003-0282-7426
Charles Q LeDepartment of Preventive and Restorative Dental Sciences, School of Dentistry, University of California, San Francisco, 707 Parnassus Avenue, San Francisco, CA, 94143, USA.
Benjamin W ChaffeeDepartment of Preventive and Restorative Dental Sciences, School of Dentistry, University of California, San Francisco, 707 Parnassus Avenue, San Francisco, CA, 94143, USA.
Beate M T RechmannDepartment of Preventive and Restorative Dental Sciences, School of Dentistry, University of California, San Francisco, 707 Parnassus Avenue, San Francisco, CA, 94143, USA.

Funding

This work is a Principal Investigator Initiated Study and was funded by Nobio Ltd. (Kadima, Israel) through the University of California, San Francisco's Industry Contracts & Grants Division. #A132487
6 · The paper itself

Abstract

objectivesTo investigate whether a newly developed dental composite with quaternary ammonium silica dioxide (QASi) nanoparticles incorporated with other fillers into the restorative material demonstrates antibacterial activity by reducing enamel demineralization in an in situ gap model. MATERIALS AND

methodsTwenty subjects wearing a lower removable partial denture (RPD) with acrylic flanges on both sides of the mouth were recruited into the 4-week in situ study. The gap model consisted of an enamel slab placed next to a composite, separated by a 38-μm space. In the split-mouth design on one side of the RPD, the composite was the Nobio Infinix composite (Nobio Ltd., Kadima, Israel), and the contralateral side used a control composite. Each participant received enamel slabs from one tooth. The gap model was recessed into the RPD buccal flange, allowing microbial plaque to accumulate within the gap. After 4 weeks of continuous wearing, decalcification (∆Z mineral loss) of the enamel slabs adjacent to the gap was determined by cross-sectional microhardness testing in the laboratory.

resultsThe ∆Z for the antibacterial composite test side was 235±354 (mean±standard deviation [SD]; data reported from 17 participants) and statistically significantly lower compared to ∆Z of the control side (774±556; mean±SD) (paired t-test, P<0.0001; mean of test minus control -539 (SD=392), 95% confidence interval of difference: -741, -338).

conclusionsThis in situ clinical study showed that composites with QASi antibacterial particles significantly reduced demineralization in enamel adjacent to a 38-μm gap over a 4-week period in comparison to a conventional composite. CLINICAL RELEVANCE: Composites with QASi nanoparticle technology have the potential to reduce the occurrence of secondary caries.

trial registrationClinicalTrials.gov #NCT04059250.

Indexed as

Dental CariesNanoparticlesTooth DemineralizationAnti-Bacterial AgentsComposite ResinsCross-Sectional StudiesDental EnamelHumansAnti-Bacterial AgentsComposite ResinsAntibacterial compositeEnamel demineralizationGap modelIn situ clinical trialQuaternary ammonium silica dioxide particlesSecondary caries

Identifiers

PMID33608748
PMCPMC7895509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.